Appili Therapeutics Inc - Asset Resilience Ratio

Latest as of March 2022: 0.00%

Appili Therapeutics Inc (APLI) has an Asset Resilience Ratio of 0.00% as of March 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Appili Therapeutics Inc to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CA$0.00

≈ $0.00 USD Cash + Short-term Investments

Total Assets

CA$8.28 Million

≈ $5.99 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2022)

This chart shows how Appili Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Appili Therapeutics Inc's balance sheet.

Liquid Assets Composition Over Time

This chart breaks down Appili Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read APLI liabilities breakdown for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CA$0.00	0%
Short-term Investments	CA$0.00	0%
Total Liquid Assets	CA$0.00	0.00%

Asset Resilience Insights

Limited Liquidity: Appili Therapeutics Inc maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

Appili Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Appili Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
CSL Ltd AU:CSL	Biotechnology	0.41%
Vaxcyte Inc NASDAQ:PCVX	Biotechnology	41.54%
Bachem Holding AG SW:BANB	Biotechnology	0.00%
Definium Therapeutics, Inc. NASDAQ:DFTX	Biotechnology	38.51%
Chongqing Zhifei Bio Products SHE:300122	Biotechnology	-0.08%
HLB Co. Ltd KQ:028300	Biotechnology	3.29%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A SHG:688076	Biotechnology	2.30%
Zhejiang Ausun Pharmaceutical Co Ltd SHG:603229	Biotechnology	0.12%

Annual Asset Resilience Ratio for Appili Therapeutics Inc (2017–2022)

The table below shows the annual Asset Resilience Ratio data for Appili Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-03-31	0.00%	CA$0.00 ≈ $0.00	CA$8.28 Million ≈ $5.99 Million	--
2021-03-31	27.63%	CA$5.06 Million ≈ $3.66 Million	CA$18.32 Million ≈ $13.25 Million	+27.36pp
2020-03-31	0.27%	CA$30.54K ≈ $22.09K	CA$11.17 Million ≈ $8.08 Million	-0.17pp
2019-03-31	0.45%	CA$30.48K ≈ $22.05K	CA$6.84 Million ≈ $4.94 Million	+0.02pp
2018-03-31	0.42%	CA$30.32K ≈ $21.93K	CA$7.19 Million ≈ $5.20 Million	-0.36pp
2017-03-31	0.78%	CA$20.14K ≈ $14.57K	CA$2.57 Million ≈ $1.86 Million	--

pp = percentage points

About Appili Therapeutics Inc

TO:APLI Canada Biotechnology

Market Cap

$928.58K

CA$1.28 Million CAD

Market Cap Rank

#30748 Global

#1593 in Canada

Share Price

CA$0.01

Change (1 day)

-33.33%

52-Week Range

CA$0.01 - CA$0.04

All Time High

CA$1.87